Biomedical research is a public service mission of health care institutions (Article L.6112.-1 of the Public Health Code and Article L.112-2 of the Research Code).

Lacassagne has consequently made biomedical research a major strategic point of focus.

In 2015, 671 patients took part in therapeutic trials through 147 open-accredited therapeutic trials.

Lacassagne has a strong teaching, training and research activity with three certified teams and a CNRS unit.

It holds a significant place as a Center in the Fight against Cancer in terms of support for investigative trials, implementation of promoter trials or inclusions.

 

 

Two major projects emerge from the Medical-Scientific Project 2014-2019 in clinical research:

ESTABLISHING AN EARLY PHASE UNIT

This structure:

  • facilitates the transfer of basic research to the clinical field,
  • has privileged access to new therapeutics to promote innovative clinical trials,
  • positions itself as a reference center for the East PACA region.

The Early Phase Therapeutic Trial Unit has 4 beds, a medical office and a Clinical Research Associate, located in the conventional B4 hospital ward. Two more beds are available within this unit. Effective and productive interaction is optimized in this setting between the basic research teams, the translational team and the clinical research teams.

ISO 9001 CERTIFICATION

The Clinical Research and Innovation Department has committed to an ISO 9001 certification process extended to the scope of the Pharmacy “Clinical Trials” sector.
This approach ensures a permanent improvement in the performance and competitiveness of the Center, while optimizing costs, positioning itself with respect to international competition, remaining attractive and being clearly identified as a clinical research network, both by the pharmaceutical industry and by our academic and institutional interlocutors.

The Scientific and Orientation Committee is made up of 12 expert members who decide on the different approaches and themes chosen by the research institution.

It meets every year end and its conclusions are not only advisory but are taken into account by the Chief Executive Officer, Head of Division, Research Teams and Clinical Research Department regarding orientation and actions to be implemented.

It operates as follows:

  • The CSO must define the broad strategic orientation of the institution in terms of research with open discussion with all stakeholders
  • The research teams are in collaboration and the topics presented must necessarily be in line with defined strategic lines. Themes must be prioritized in terms of feasibility, their interest and the investment that the projects represent
  • The activity of the Clinical Research and Innovation Department must be presented, highlighting the strengths and weaknesses, which will help refine the strategic axes